Skip to content

Clinical trials

Completed Phase 1 Myelodysplastic Syndromes trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Phase: Phase 1 Status: Completed Clear all

228 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20007
20012
20029
20034
20044
200513
20064
200712
200811
200914
201010
20119
201213
201310
201414
201512
20167
201712
201811
201910
20208
20214
20222
20232
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed228

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center15
National Cancer Institute (NCI)13
Washington University School of Medicine10
Memorial Sloan Kettering Cancer Center9
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8
Celgene5
St. Jude Children's Research Hospital5
SymBio Pharmaceuticals5
Case Comprehensive Cancer Center4
Masonic Cancer Center, University of Minnesota4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes228
Leukemia, Myeloid, Acute157
Leukemia88
Precursor Cell Lymphoblastic Leukemia-Lymphoma79
Leukemia, Myelomonocytic, Chronic63
Leukemia, Lymphocytic, Chronic, B-Cell49
Lymphoma, Non-Hodgkin49
Multiple Myeloma46
Hodgkin Disease44
Lymphoma39

Trials

Showing 1 to 25 of 228. Each trial links to its page on Pharma Observatory.

128 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.